Sareum Holdings PLC 2019 AR2
The report outlines Sareum Holdings plc's progress in its drug discovery programmes for cancer and autoimmune diseases during the fiscal year ended June 30, 2019. The company advanced its proprietary selective TYK2/JAK1 inhibitors, SDC-1801 and SDC-1802, through preclinical development, with SDC-1801 demonstrating excellent tolerability in toxicology studies. Additionally, positive preliminary clinical data was presented for the licensed Chk1 inhibitor SRA737. Financially, the company raised GBP 850,000 in November 2018 and completed a further placing of GBP 781,484 in July 2019 to fund its ongoing research and working capital.
Company: Sareum Holdings PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2019
Type: AR2
Pages: 48
Back to company
Sareum Holdings PLC
Annual Report And Accounts
The report outlines Sareum Holdings plc's progress in its drug discovery programmes for cancer and autoimmune diseases during the fiscal year ended June 30, 2019. The company advanced its proprietary selective TYK2/JAK1 inhibitors, SDC-1801 and SDC-1802, through preclinical development, with SDC-1801 demonstrating excellent tolerability in toxicology studies. Additionally, positive preliminary clinical data was presented for the licensed Chk1 inhibitor SRA737. Financially, the company raised GBP 850,000 in November 2018 and completed a further placing of GBP 781,484 in July 2019 to fund its ongoing research and working capital.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jul 1, 2018 - Jun 30, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees